| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | 0.0076 | 0.9 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.024 | 0.9 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | 0.0065 | 0.9 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.014 | 0.9 |